Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Grünenthal GmbH Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
---|---|
Information provided by: | Grünenthal GmbH |
ClinicalTrials.gov Identifier: | NCT00486811 |
The purpose of this study is to evaluate whether CG5503 prolonged-release (PR) tablets at doses of 100-250 mg twice daily provide a better pain relief in patients with moderate to severe chronic pain due to osteoarthritis of the knee than a placebo (a medication without active substance). In addition the tolerability of CG5503 PR will be assessed. One third of the patients will receive CG5503 and one third will receive placebo. For further comparison one third of the patients will receive oxycodone controlled release (CR) at doses of 20-50 mg twice daily which is an active approved pain medication.
Condition | Intervention | Phase |
---|---|---|
Pain Knee Osteoarthritis |
Drug: CG5503, centrally acting analgesic Drug: Placebo Drug: CG5503 Drug: Oxycodone |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Randomized Double-Blind, Placebo- and Active-Control, Parallel-Arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee. |
Estimated Enrollment: | 1200 |
Study Start Date: | June 2007 |
Study Completion Date: | July 2008 |
Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator |
Drug: Placebo
Placebo BID
|
2: Experimental |
Drug: CG5503, centrally acting analgesic
CG5503 PR 100 mg - 250 mg BID
Drug: CG5503
CG5503 PR 100 mg - 250 mg BID
|
3: Active Comparator |
Drug: Oxycodone
Oxycodone CR, 20 mg - 50 mg BID
|
This is a randomized (study medication assigned to patients by chance), double-blind (neither patient nor investigator knows which patient gets which study medication, i.e. CG5503, placebo, oxycodone), placebo and active control study. The primary objective is to evaluate the efficacy and safety of orally administered CG5503 prolonged-release (PR) at doses of 100-250 mg (base) twice daily in patients with moderate to severe chronic pain from osteoarthritis (OA) of the knee. The study is being conducted for registration and approval of CG5503 in Europe and outside Europe. The study will consist of five periods: screening (to assess eligibility), washout (3-7 days with determination of a baseline pain intensity), titration (of dose over 3 weeks to the optimal individual level), maintenance (investigational drug intake for 12 weeks with adjustments allowed), and follow-up (2 weeks after end of treatment). The study hypothesis is that the study drug will be more effective than placebo in reducing patients' pain intensity. The secondary objectives include the collection of pharmacokinetic (related to how the body absorbs, distributes, changes and excretes the drug) information for dose verification.
The efficacy objectives will be assessed by comparing the baseline pain level to the pain level during the maintainence period. This will be done by looking at the patients' pain diary information (electronic diaries).
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Principal Investigator: | Alain Serrie, Dr. | C.E.T.D Hôpital Lariboisière |
Responsible Party: | Grünenthal GmbH ( Grünenthal GmbH ) |
Study ID Numbers: | 335862 |
Study First Received: | June 14, 2007 |
Last Updated: | September 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00486811 History of Changes |
Health Authority: | Czech Republic: SUKL (State Institute for Drug Control); France: AFSSAPS (Agence Francaise de Securite); Germany: Bundesinstitut für Arzneimittel und Medizinprodukte; Hungary: OGYI (National Hungarian Institute of Pharmacy); Italy: IRCCS Ospedale Maggiore di Milano; Latvia: State Agency of Medicines; Netherlands: CCMO (Central Commissie Mensgebonden Onderzoek); Poland: CEBK (Centralna Ewidencja Badan Klinicznych); Portugal: Board of Hospital Distrital de Faro; Portugal: Board of Hospital Do Divino Espirito Santo de Ponta Delgada; Portugal: Board of Hospitalda Universidade de Coimbra; Portugal: Board of Hospital des. Hospital Senhora da Oliveira Guimaraes; Portugal: Board of Hospital Central do Funchal; Portugal: Board of Instituto de Reumatologia Lisboa; Romania: National Medicine Agency; Spain: AEMPS (Agenica Espanola de Medicamentos y Productos Sanitarios) |
Osteoarthritis Knee Pain Assessment CG5503 PR |
Centrally acting analgesic Placebo Oxycodone Chronic Pain due to knee Osteoarthritis |
Osteoarthritis Joint Diseases Oxycodone Central Nervous System Depressants Pain Narcotics Rheumatic Diseases |
Osteoarthritis, Knee Musculoskeletal Diseases Arthritis Analgesics Peripheral Nervous System Agents Analgesics, Opioid |
Osteoarthritis Joint Diseases Oxycodone Physiological Effects of Drugs Central Nervous System Depressants Narcotics Rheumatic Diseases Pharmacologic Actions Osteoarthritis, Knee |
Musculoskeletal Diseases Sensory System Agents Therapeutic Uses Arthritis Analgesics Peripheral Nervous System Agents Central Nervous System Agents Analgesics, Opioid |